Finoriq research workspace
ARTELO BIOSCIENCES, INC. (ARTL) SEC Filings & Filing Highlights
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes. Review ARTL SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
- Company
- ARTELO BIOSCIENCES, INC. (ARTL)
- Ticker
- ARTL
- Market Cap
- $3.9M
- Latest Price
- $1.13
- Industry
- Biotech & Pharma
ARTELO BIOSCIENCES, INC. (ARTL) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ARTELO BIOSCIENCES, INC. (ARTL).
| Event | Form | Date |
|---|---|---|
| ARTELO BIOSCIENCES, INC.: Corporate updateOn April 7, 2026, Craft Capital Management LLC (“Craft”) filed a FINRA arbitration claim against the Company seeking compensatory damages,... | 8-K8.01 | 2026-05-27 |
| ARTELO BIOSCIENCES, INC.: Material agreementOn May 26, 2026, Artelo Biosciences, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C... | 8-K1.01 | 2026-05-27 |
| Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly cause...On May 11, 2026, Artelo Biosciences, Inc. (the “Company”) provided notice to R.F. Lafferty & Co., Inc. (“R.F. Lafferty”) of its election to... | 8-K1.02 | 2026-05-15 |
| Artelo Biosciences Regains Compliance with Nasdaq Listing RequirementsArtelo Biosciences Regains Compliance with Nasdaq Listing Requirements | 8-K8.01 | 2026-04-07 |
| Artelo Biosciences Announces $11.0 Million Private PlacementArtelo Biosciences Announces $11.0 Million Private Placement | 8-K8.01 | 2026-03-30 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.